순번 | 임상시험 제목 | 적응증 | 연구설계 | 의뢰자/실시기관 | 임상단계 | NCT No | 개시일자 |
---|---|---|---|---|---|---|---|
1 | Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract | Allergic Rhinitis|Allergic Asthma|Allergic Rhinoconjunctivitis|Allergy to House Dust Mite | Biological: 3,000 MM09|Biological: 9,000 MM09|Other: Placebo sublingual | Inmunotek S.L.|LAT Research|Xolomon Tree S.L. | Phase 2|Phase 3 | 2023-04-01 | |
2 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse Large B-Cell Lymphoma | Drug: Epcoritamab|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone | AbbVie|Genmab | Phase 3 | 2023-02-08 | |
3 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | Melanoma | Biological: Pembrolizumab/Vibostolimab|Biological: Pembrolizumab | Merck Sharp & Dohme LLC | Phase 3 | 2023-01-19 | |
4 | Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) | COVID-19, SARS-CoV-2 | Biological: AZD5156 (Sentinel Safety Cohort)|Biological: Placebo (Sentinel Safety Cohort)|Biological: AZD7442 (EVUSHELD™) (Main Cohort)|Biological: AZD3152 (Main Cohort) | AstraZeneca | Phase 3 | 2022-12-16 | |
5 | A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Alzheimers Disease|Dementia|Alzheimers Disease, Familial | Drug: Gantenerumab|Drug: Matching Placebo (Gantenerumab) | Washington University School of Medicine|Hoffmann-La Roche|Alzheimer's Association|National Institute on Aging (NIA)|Genentech, Inc. | Phase 2|Phase 3 | 2022-12-02 | |
6 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | Drug: Upadacitinib|Drug: Dupilumab | AbbVie | Phase 3 | 2022-11-28 | |
7 | Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) | Pneumococcal Disease | Biological: V116|Biological: PPSV23 | Merck Sharp & Dohme LLC | Phase 3 | 2022-11-07 | |
8 | Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis | Tuberculosis, Pulmonary | Biological: RUTI® Vaccine|Biological: Placebo | Archivel Farma S.L. | Phase 2 | 2022-10-29 | |
9 | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above | Respiratory Syncytial Virus Infections | Biological: RSVPreF3 OA investigational vaccine|Drug: Placebo | GlaxoSmithKline | Phase 3 | 2022-10-28 | |
10 | A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis|Eczema | Drug: Lebrikizumab|Drug: Placebo|Drug: Topical corticosteroid | Eli Lilly and Company|Dermira, Inc. | Phase 3 | 2022-10-18 |